The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

BACKGROUND: Trastuzumab treatment for women with HER2-positive breast cancer (BC) resulted in the significant improvement of both relapse free survival (RFS) and overall survival (OS). However, many women who are classified as HER2-positive do not respond. Many studies have focused on the role of so...

Descripción completa

Detalles Bibliográficos
Autores principales: Toomey, Sinead, Madden, Stephen F., Furney, Simon J., Fan, Yue, McCormack, Mark, Stapleton, Carragh, Cremona, Mattia, Cavalleri, Gianpiero L., Milewska, Malgorzata, Elster, Naomi, Carr, Aoife, Fay, Joanna, Kay, Elaine W., Kennedy, Susan, Crown, John, Gallagher, William M., Hennessy, Bryan T., Eustace, Alex J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342757/
https://www.ncbi.nlm.nih.gov/pubmed/27776352
http://dx.doi.org/10.18632/oncotarget.12782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342757/
https://www.ncbi.nlm.nih.gov/pubmed/27776352
http://dx.doi.org/10.18632/oncotarget.12782

Ejemplares similares